Key Highlights

• Nyrada is raising about AUD 14mn through a Placement and Security Purchase Plan.

• The Offer Price is AUD 0.62 per new CDI, with attaching Options included.

• Capital supports PROTECT-MI Phase IIa execution and broader TRPC inhibitor development.

• The company maps multiple clinical and preclinical milestones across the next 18 months.

Nyrada Inc (ASX:NYR) has outlined an approximately AUD 14mn capital raising as it advances its TRPC-based therapy pipeline. The funding package comprises an institutional placement targeting AUD 12mn before costs and a Security Purchase Plan targeting up to about AUD 2mn. The placement includes a conditional director component of approximately AUD 5.1mn, subject to CDI-holder approval at an extraordinary general meeting expected around February 2027. New CDIs under the placement and SPP are priced at AUD 0.62 each.

Options Add Another Layer to the Offer

Participants are scheduled to receive three free-attaching quoted options for every four new CDIs subscribed for, exercisable at AUD 0.93 and expiring on 24 September 2028. Placement participants may also receive a piggyback option after exercising each attaching option, with those piggyback options exercisable at AUD 1.40 and expiring on 25 September 2030. The treatment of piggyback options for SPP participants depends on an ASIC modification described in the presentation.

Clinical Programme Sets the Near-Term Agenda

The development timetable centres on PROTECT-MI Phase IIa, including patient recruitment and site activations across Australian PCI-capable hospitals, an early safety review and expansion of the trial-site network. The presentation also identifies regulatory engagement, further preclinical oncology and cardioprotection work, development of a next-generation orally dosed TRPC inhibitor and a preclinical middle cerebral artery occlusion study as milestones across the programme.

Company Introduction

Nyrada is developing therapies based on inhibition of transient receptor potential canonical, or TRPC, ion channels. Its lead clinical asset, Xolatryp, is being developed across cardiovascular and other potential indications. The capital raising presentation also outlines translational oncology work and a broader neuroprotection programme.

Sector Context

Healthcare biotechnology companies operate against changing funding conditions, input costs, regulatory requirements and end-market demand. For project developers and explorers, technical results, approvals, development studies and access to capital can materially alter timelines. For healthcare developers, clinical outcomes and regulatory progress are central. Financial businesses remain sensitive to capital allocation, funding costs, asset quality and market conditions. These sector factors provide context, but the company's own disclosed milestones remain the primary measure of execution.

Risks to Consider

Execution remains the central consideration. Timelines can move, approvals or transaction conditions may take longer than expected, and funding needs can change as programmes advance. Exploration and development outcomes may differ from expectations, while clinical programmes face safety, efficacy and regulatory uncertainty. Corporate transactions can also remain conditional until completion. These factors mean that announced targets and schedules should be assessed against subsequent company updates.

Things to Watch Next

The next items to watch are the milestones set out in the company's announcement, including completion of scheduled funding or transaction steps, delivery of technical or operational work and any required approvals. Follow-up announcements will show whether the current programme remains on schedule and whether new information changes the scope, cost or timing of the next phase.

Summary

Nyrada Inc's latest update puts execution of the announced programme at the centre of the next phase, with funding, technical delivery and scheduled milestones providing the clearest markers to follow.